Andy Ramelmeier

Andy Ramelmeier currently serves as the Chief Technology Officer at Adverum Biotechnologies since August 2023. Prior to this role, Andy held multiple positions at Sangamo Therapeutics, Inc., including EVP and SVP of Technical Operations from January 2018 to July 2023. Andy also served as SVP of Technical Operations Biologics at Portola Pharmaceuticals from 2014 to 2017. At BioMarin Pharmaceutical Inc., from 2006 to 2014, Andy was VP of Global Manufacturing and Facilities and VP of Manufacturing, Process Sciences and Facilities, responsible for significant manufacturing operations and overseeing large teams across multiple facilities. Additional experience includes roles as VP of Process Sciences at J&J and Executive Director at Centocor R&D, Inc. In the early career, Andy was a Senior Research Fellow at Merck, focusing on BioProcess R&D. Academic credentials include a PhD in Chemical Engineering from the University of California, Berkeley, along with post-doctoral work supported by the Alexander von Humboldt Foundation and research on protein purification in Germany. Andy holds a BS in Chemical Engineering from The Johns Hopkins University.